glp-1 with cv benefit The cardiovascular effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 RAs in T2D and

andchapter royalties from UpToDate

These peptides were glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)

Regular check-ins with your healthcare provider are essential for safe and effective use

The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes

Our survey found that over 75% of health plans and over 50% of employers are moderately or very concerned about off-label use, but awareness of how much current spend is off-label is notably lower: nearly half of employers and a quarter of health plans are unsure

This is why the GLP-1 analogues market is no longer just a weight loss drug market